ALP Bio raises €161K from Venture Kick to improve the safety of biologic medicines

ALP Bio is developing an AI-powered platform that helps drug developers identify immune-related risks earlier in the development process, supporting the design of safer biologic medicines and advancing collaborations with pharmaceutical partners.

venerdì 3 luglio 2026 New tab

238 words~1 min read

Swiss biotech

startup ALP Bio has secured €161,000 (CHF 150,000) from Venture Kick to support

the commercial development of its platform, which helps drug developers

identify immune-related risks earlier in the development process. By combining

human immune tissue models with artificial intelligence, the company aims to

ALP Bio raises €161K from Venture Kick to improve the safety of biologic medicines — Warptech Lab News